Fat-Derived Stem Cells for Spinal Injury and BRCA Immune Insight Featured on Naked Scientists

The Naked Scientists episode features a first-in-human trial using mesenchymal stem cells derived from a patient’s own abdominal fat to support recovery after spinal cord injury, alongside a Cambridge study examining immune cell changes in BRCA1 and BRCA2 gene carriers that may inform cancer prevention strategies. The program also delves into dinosaur growth history through bone histology and the idea that temporal resolution varies among individuals and could influence performance in fast sports. A practical Q&A on glucose spikes from meal order rounds out the science overview.

• Fat-derived mesenchymal stem cells injected into thecal sac show mostly mild to significant improvements in a small phase one trial.
• Immune exhaustion observed in BRCA gene carriers may point to preventive pharmacology before tumor formation.
• Early dinosaurs and related reptiles exhibited rapid growth, suggesting environmental pressures after mass extinction shaped growth strategies.
• Human temporal resolution varies widely and may influence high speed perception and sport performance.

Overview

The Naked Scientists program presents a multi-topic examination of current science, beginning with a phase one trial investigating stem cell therapy for spinal cord injuries and followed by a genetics study from Cambridge on BRCA1 and BRCA2 mutation carriers. The episode also features a paleontology discussion on dinosaur growth using bone histology and a cognitive science segment on temporal resolution in human vision. The format combines expert interviews and explanations suitable for a general science audience.

Fat-Derived Stem Cells for Spinal Cord Injury

In an early American trial, researchers harvested mesenchymal stem cells from a patient’s abdominal fat, expanded them to about 100 million cells, and injected them into thecal sac around the spinal cord. The aim was to enhance blood supply and modulate inflammation in injured areas, potentially reducing scar formation and restoring some nerve connectivity. The trial included 10 patients who had sustained injuries up to 22 months prior, with the earliest treatment at seven months post-injury. The cells were confirmed to be stem cells by marker analysis and were observed to migrate to areas of highest injury and inflammation after administration.

Safety data indicated mostly transient headaches or back pain without significant long-term adverse effects. In terms of effectiveness, seven of the ten patients showed some improvement, including three with substantial gains and four with mild to moderate improvements. Improvements also extended to bowel and bladder function, and some patients who required assistive devices could stand and walk unaided. Importantly, the study was a phase one, non-randomized trial, and the researchers are moving toward a randomized, controlled phase two trial comparing best medical management against the interventional therapy.

Stem Cell Source, Dosing, and Mechanisms

The cells used were adipose-derived mesenchymal stem cells, indicating the therapeutic potential of a patient’s own fat as a source. The dosing target was 100 million cells at the time of injection; however, the team acknowledged that dosing optimization remains an open question. The injection occurs into the thecal sac surrounding the spinal cord and cerebrospinal fluid, allowing cells to home toward injured tissue. Proposed mechanisms include direct regenerative potential of stem cells and a vascular mechanism in which stem cells help restore vasculature in damaged areas, enabling nutrient delivery and waste removal to support healing.

Cambridge BRCA Tissue Study and Immune Exhaustion

A Cambridge team performed single cell sequencing on donated breast tissues from individuals with different BRCA gene statuses, including healthy carriers and those with BRCA mutations. They found a higher density of immune cells in BRCA-altered tissues and signs of immune exhaustion, a state normally associated with late-stage cancer. The observed chronic inflammatory milieu may pre‑empt tumor formation and reveal opportunities for preventive therapy using existing clinical drugs that target these cellular processes.

These findings imply that the BRCA mutation carriers’ tissues experience early immune dysfunction that could contribute to cancer risk, and that intervening before tumor formation might be a viable strategy. The researchers emphasized that such preventive approaches would require preclinical validation and careful consideration of drug side effects before moving toward clinical trials in preventive oncology. The study was published in Nature Genetics with authors Austin Reed and Sarah Pentzer from the University of Cambridge.

Broader Implications: Prevention Across Organs

The Cambridge team suggested that similar single-cell analyses could be applied to other BRCA-linked tissues, such as the prostate and ovaries, to assess whether comparable inflammatory and immune-suppressive dynamics occur. They noted that several drugs already exist to target these cellular pathways in cancer treatment and could be repurposed for preventive strategies in individuals at high genetic risk, pending rigorous preclinical evaluation.

Other Topics in the Episode

In the dinosaur segment, researchers used bone histology to infer growth rates, discovering elevated growth rates in early dinosaurs and many non-dinosaur relatives, suggesting that rapid growth was a widespread response to the ecological pressures following the most severe mass extinction. The episode also explores how rapid visual processing may confer advantages in fast moving sports and predator-prey contexts, based on work from Trinity College Dublin examining human temporal resolution. A question of the week addresses glucose spikes in diabetics and how meal composition and order can modulate postprandial glucose responses, with guidance from Cambridge researchers.

Takeaways

The show highlights cutting edge regenerative medicine approaches and the potential for preventive oncology guided by tissue- and cell-level insights. It also demonstrates how paleontological methods can illuminate evolutionary biology and how perceptual neuroscience can translate into practical performance considerations.